348 related articles for article (PubMed ID: 33719967)
1. Tocilizumab: From Rheumatic Diseases to COVID-19.
Raiteri A; Piscaglia F; Granito A; Tovoli F
Curr Pharm Des; 2021; 27(13):1597-1607. PubMed ID: 33719967
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
4. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.
Cortegiani A; Ippolito M; Greco M; Granone V; Protti A; Gregoretti C; Giarratano A; Einav S; Cecconi M
Pulmonology; 2021; 27(1):52-66. PubMed ID: 32713784
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
7. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
9. Systematic Review on Treatment Trials of Tocilizumab: A Repurposing Drug against COVID-19.
Banerjee S; Mahapatra AK
Rev Recent Clin Trials; 2021; 16(4):381-389. PubMed ID: 34429051
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tocilizumab in COVID-19: A review of the current evidence.
Alam W; Bizri AR
Sci Prog; 2021; 104(3):368504211030372. PubMed ID: 34236264
[TBL] [Abstract][Full Text] [Related]
11. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Coskun Benlidayi I; Kurtaran B; Tirasci E; Guzel R
Rheumatol Int; 2020 Oct; 40(10):1707-1716. PubMed ID: 32591970
[TBL] [Abstract][Full Text] [Related]
12. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.
Jordan SC; Zakowski P; Tran HP; Smith EA; Gaultier C; Marks G; Zabner R; Lowenstein H; Oft J; Bluen B; Le C; Shane R; Ammerman N; Vo A; Chen P; Kumar S; Toyoda M; Ge S; Huang E
Clin Infect Dis; 2020 Dec; 71(12):3168-3173. PubMed ID: 32575124
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
Samaee H; Mohsenzadegan M; Ala S; Maroufi SS; Moradimajd P
Int Immunopharmacol; 2020 Dec; 89(Pt A):107018. PubMed ID: 33045577
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.
Bacca E; Digaetano M; Meschiari M; Franceschini E; Menozzi M; Cuomo G; Mussini C
Biochem Biophys Res Commun; 2021 Jan; 538():151-155. PubMed ID: 33303188
[TBL] [Abstract][Full Text] [Related]
15. Treatment of COVID-19-induced refractory status epilepticus by tocilizumab.
Kizilkilic EK; Unkun R; Uygunoglu U; Delil S; Ozkara C
Eur J Neurol; 2022 Sep; 29(9):2861-2863. PubMed ID: 35678591
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
17. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
18. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
19. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
20. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
Masuccio FG; Lo Re M; Bertolotto A; Capobianco M; Solaro C
Mult Scler Relat Disord; 2020 Nov; 46():102592. PubMed ID: 33296987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
